Abattis Bioceuticals Corp. (ATTBF)

38d6d7dAbattis Bioceuticals Corp is a Canada-based specialty company that delves in the biotechnology, cultivation, licensing, and distribution of cannabis and related products. Through its subsidiary companies and with industry partners, the company is aiming to capitalize on both Canada and US marijuana markets.

One of Abattis’ wholly owned subsidiaries is Biocube Green Grow Systems Corp, which provides controlled cultivation environments. This company has exclusive rights to the MgO board, a special building product touted as fireproof, waterproof, antimicrobial, and recyclable.

Another subsidiary is iJuana Cannabis, Inc, the cannabis-growing arm and end-consumer representative of Abattis Bioceuticals. It has a 27,000-square foot facility in Squamish, British Columbia.

Abattis also owns Biocell Labs, Inc. This wholly owned subsidiary focuses on supplying pharmaceutical, nutraceutical, and cosmetic cannabis formulations. It currently has proprietary technologies for extraction, as well as 13 proprietary formulations ready for out-licensing.

Meanwhile, North America Bioextracts is the Abattis Bioceuticals subsidiary that develops and retails cannabis products, including extract oils and vaporizer flavors. This company has offices in Canada and Washington State.

Finally, Northern Vine Canada, Inc is a processing, testing, and packaging subsidiary of Abattis. With a facility in Langley, British Columbia, it also offers analytical services for licensed cannabis producers.

Aside from these subsidiaries, Abattis Bioceuticals has partnerships with PhytaLab for testing, Experion Bio Technologies, Inc for developing cannabis strains, and Instant Payment Systems for transactions.

Abattis Bioceuticals was incorporated in 1997, and was known as Abattis Biologix Corp until 2012. It currently trades in OTC markets as ATTBF with a market cap of USD 14.55 M. Company executives include Michael Withrow, Chairman, CEO, and President; Gilbert G. Schneider, Consultant; Rene David, CFO and COO; and Jason Anderson, VP of Finance.

Yahoo! Finance: ATTBF News

Latest Financial News for ATTBF

Abattis Announces Successful Closing of Pro Natura Acquisition

Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”). Abattis is also pleased to announce that it will be relaunching its Company Newsletter (the “Newsletter”), which has been designed to complement the Company’s continuous disclosure, and provide cannabis industry highlights as they pertain to the Company.

Abattis Announces Acquisition of European Nutraceutical Company and Provides Corporate Updates

VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that its wholly-owned subsidiary, 1185277 B.C. Ltd. (the "Acquisition Subsidiary"), has entered into a share purchase agreement (the "Agreement") to acquire (the "Acquisition") Pro Natura BV ("Pro Natura"), a privately held nutraceutical company based in Oisterwijk, Netherlands. Pro Natura has over 30 years of operations and sales experience in Europe, with over 100 products that have been marketed to both long-term repeat customers and new large groups of distributors. Pro Natura has been supported by a seasoned management team that still includes its original founder and has historically boasted €10M+ in per annum sales.

Abattis Announces Resignation of Directors

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.About Abattis Bioceuticals Corp.Abattis is positioned to be ...

Abattis Provides Update on Conference Call

Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) provides the following update on the Company’s recent trading halt and upcoming conference call with Company management that was previously set for March 1, 2019. Further to the Company’s news release dated February 18, 2019, trading of the Company’s common shares continues to be halted on the Canadian Securities Exchange until the Company files its financial statements for the year ended September 30, 2018 (the “Financials”).

Abattis Provides Update on Trading Halt and Announces Management Conference Call

Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide the following update on the Company’s recent trading halt and upcoming conference call with Company management set for March 1, 2019. On February 4, 2019, the trading of the Company’s common shares was halted due to the Company’s failure to file its year-end financial statements within the 90 day filing deadline required under National Instrument 51-102 – Continuous Disclosure Requirements.  The Company is still undergoing its year-end financial statement audit and believes it will have them filed in the coming week.